Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to ...

On the sell side, ARK trimmed its holdings in several companies, with the most notable sale being 61,072 shares of SHOPIFY INC (NYSE:SHOP), valued at $10,691,264. This followed a pattern of reducing ...

Virtus LifeSci Biotech Clinical Trials ETF BBC is probably on the radar for investors seeking momentum. The fund just hit a 52-week high and moved up 138.3% from its 52-week low price of $13.42/share.

Another major investment by ARK was the acquisition of 385,585 shares of Block Inc (NYSE:XYZ), a financial services and mobile payment company formerly known as Square, with a total value of ...

The buyout of one biotechnology company can sometimes hurt the shares of its competitors, as investors may feel like they picked the wrong merger candidate. But not in the case for those who bought ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

BIB ETF is best suited for high-risk, active investors in the accumulation phase or retirees managing portfolios hands-on.

How a US SOL ETF could shift access, flows and usage — plus the key metrics to watch to see whether Solana outperforms Ether. ETH ETFs have opened access, but flows remain cyclical. SOL’s plumbing is ...

VanEck Biotech ETF focuses on major biotech firms, offering lower volatility than smaller peers. This is a passive ETF, capturing the MVIS US Listed Biotech 25 Index without picking stocks actively.

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one ...

The estimated $8.1 million transaction represented about 1% of fund assets at the end of the quarter. Destiny Wealth now owns 16,430 shares valued at $2.4 million, which is about 0.3% of the firm's ...